Market Place
Sourcing Support
Evergreen Theragnostics Opens Phase II Trial In EU For Lung Cancer
18 Oct 2024 //
PR NEWSWIRE
Evergreen Licenses EVG321, Enters Radioligand Therapy For SCLC
21 May 2024 //
PR NEWSWIRE
Evergreen $26M For Radiopharmaceuticals, CDMO Expansion
16 Apr 2024 //
PR NEWSWIRE
UPPI and Evergreen Announce Partnership for Sales and Distribution of Octevy
25 Sep 2023 //
PR NEWSWIRE
Jubilant Radiopharma and Evergreen Theragnostics Announce Collaboration
23 Jun 2023 //
PR NEWSWIRE
Evergreen Theragnostics and PharmaLogic Announce Partnership
13 Jun 2023 //
PR NEWSWIRE
Evergreen Theragnostics Completes $15M Series B
13 Mar 2023 //
PR NEWSWIRE
Evergreen Theragnostics Completes $15M Series B, Launches Discovery Unit
13 Mar 2023 //
CONTRACT PHARMA
Evergreen Submits NDA for Gallium-68 DOTATOC Kit with US FDA
12 Dec 2022 //
PRNEWSWIRE
Evergreen Theragnostics to Manufacture MTTI’s EvaThera Radiopharmaceuticals
01 Dec 2021 //
CONTRACTPHARMA
TrialStat adopts Pure Storage solutions to expedite clinical trial research
13 Nov 2021 //
CLINICALTRIALSARENA
Evergreen Theragnostics Completes New Jersey Manufacturing Facility
18 Oct 2021 //
PRNEWSWIRE
Clarity and Evergreen Enter Clinical Manufacturing Agreement
05 Oct 2021 //
CONTRACTPHARMA
Cellectar, Evergreen Enter Clinical Manufacturing and Supply Agreement
17 Aug 2021 //
CONTRACT PHARMA
Evergreen Expands Alpha Radiopharmaceutical Production Capabilities
21 Jul 2021 //
CONTRACT PHARMA
Evergreen and ICON partner for Phase II Covid-19 drug trial
21 Jun 2021 //
CLINICAL TRAILS ARENA
Evergreen Agreement with ICON to Conduct Ph II Clinical Trial for COVID-19 Drug
18 Jun 2021 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.